

# Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

polymorphonuclear leukocyte activation and phagocytosis

antibody dependent cellular cytotoxicity by natural killer cells

